Want to see RNA full AI Analyst Report?
Top Page
Atrium Therapeutics, Inc.
(NASDAQ:RNA)
Select Model
Select Model
Rating:50Neutral
Price Target:
$13.00
▼(-7.01% Downside)
Action:Reiterated
Date:08/19/26
The score is primarily held back by weak financial performance—large net losses and persistent, sizable cash burn—despite the benefit of low leverage. Technical indicators provide a partial offset with moderately positive momentum, while valuation is constrained by a negative P/E and no dividend yield data.
Positive Factors
Strategic BMS partnership and milestone economics
The Bristol Myers Squibb collaboration provides non-dilutive milestone potential, royalty upside and validation from a major pharmaceutical partner. BMS funding future clinical, regulatory and commercialization work could materially reduce Atrium’s development burden.
Negative Factors
Persistent cash burn and funding dependence
Sustained operating and free-cash-flow deficits indicate that Atrium cannot currently fund development from internal operations. Continued reliance on external capital may create dilution or financing risk and could constrain investment if funding conditions deteriorate.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic BMS partnership and milestone economics
The Bristol Myers Squibb collaboration provides non-dilutive milestone potential, royalty upside and validation from a major pharmaceutical partner. BMS funding future clinical, regulatory and commercialization work could materially reduce Atrium’s development burden.
Read all positive factors
Atrium Therapeutics, Inc. (RNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$239.14M
Dividend YieldN/A
Average Volume (3M)2.09M
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees511
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,105,642
10 Day Avg. Volume2,820,857
30 Day Avg. Volume2,094,181
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.22
Price to Sales (P/S)13.56
P/FCF Ratio-5.93
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$25.00Price Target Upside78.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Atrium Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently...
Atrium Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
23
Negative
Balance Sheet
64
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.97M | 18.62M | 10.90M | 9.56M | 9.22M | 9.33M |
| Gross Profit | 35.48M | 18.62M | 10.90M | 7.46M | 7.84M | -91.86M |
| EBITDA | -260.06M | -76.50M | -376.16M | -233.50M | -177.53M | -117.41M |
| Net Income | -259.33M | -76.68M | -322.30M | -212.22M | -174.00M | -118.01M |
Balance Sheet | ||||||
| Total Assets | 280.51M | 278.35M | 1.56B | 628.55M | 638.80M | 427.58M |
| Cash, Cash Equivalents and Short-Term Investments | 264.21M | 270.00M | 1.50B | 595.35M | 610.73M | 405.54M |
| Total Debt | 1.68M | 3.67M | 6.80M | 9.85M | 10.69M | 11.73M |
| Total Liabilities | 65.94M | 71.07M | 138.94M | 127.79M | 60.73M | 46.15M |
| Stockholders Equity | 214.58M | 207.29M | 1.42B | 500.76M | 578.08M | 381.43M |
Cash Flow | ||||||
| Free Cash Flow | -217.39M | -42.57M | -307.94M | -123.29M | -139.09M | -98.55M |
| Operating Cash Flow | -210.49M | -41.13M | -300.87M | -119.06M | -136.27M | -94.81M |
| Investing Cash Flow | -782.49M | -1.45M | -854.20M | -130.07M | -189.96M | -82.52M |
| Financing Cash Flow | 1.17B | 42.57M | 1.19B | 93.86M | 346.17M | 176.32M |
Atrium Therapeutics, Inc. Technical Analysis
Negative
13.98
Price Trends
Market Momentum
0.14
Positive
58.43
Neutral
29.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNA, the sentiment is Negative. The current price of 13.98 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 58.43 is Neutral, neither overbought nor oversold. The STOCH value of 29.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNA.
Atrium Therapeutics, Inc. Risk Analysis
Atrium Therapeutics, Inc. disclosed 92 risk factors in its most recent earnings report. Atrium Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Atrium Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | $397.38M | -24.13 | -5.76% | ― | ― | 93.45% | |
52 Neutral | $459.60M | -4.56 | -46.54% | ― | -82.95% | -49.04% | |
51 Neutral | $231.85M | -2.79 | -91.60% | ― | 3472.96% | 67.74% | |
50 Neutral | $239.14M | -3.54 | -39.08% | ― | ― | ― | |
49 Neutral | $283.07M | -1.76 | -57.61% | ― | -94.10% | -122.58% | |
48 Neutral | $301.65M | -1.62 | 141.41% | ― | ― | ― |
* General Sector Average
RNA
Atrium Therapeutics, Inc.
13.64
-1.11
-7.53%
ARCT
Arcturus Therapeutics
15.19
-1.82
-10.70%
RCKT
Rocket Pharmaceuticals
3.86
0.58
17.68%
RNAC
Cartesian Therapeutics
9.60
-0.45
-4.48%
DTIL
Precision BioSciences
7.78
2.88
58.78%
TRDA
Entrada Therapeutics Inc
7.00
1.53
27.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.